Results Generated From:
EMBASE <1980 to 2010 Week 38>
EMBASE (updates since 2010-09-16)
<1>
Accession Number
2010492992
Authors
Inaba Y. Chen J.A. Bergmann S.R.
Institution
(Inaba) Division of Cardiovascular Medicine, Oregon Health and Science
University, UHN62, 3181 SW Sam Jackson Park Rd., Portland, OR 97239,
United States
(Chen, Bergmann) Division of Cardiology, Beth Israel Medical Center, New
York, NY, United States
Title
Quantity of viable myocardium required to improve survival with
revascularization in patients with ischemic cardiomyopathy: A
meta-analysis.
Source
Journal of Nuclear Cardiology. 17 (4) (pp 646-654), 2010. Date of
Publication: August 2010.
Publisher
Springer New York (233 Springer Street, New York NY 10013-1578, United
States)
Abstract
Background: This meta-analysis was conducted to determine optimal cutoff
values for the assessment of viability using various imaging techniques
for which revascularization would offer a survival benefit in patients
with ischemic cardiomyopathy (ICM). Methods and Results: We searched five
electronic databases to identify relevant studies through December 2008.
Relative risks of cardiac death, both in patients with and without
viability, were calculated in each study. In order to estimate the optimal
threshold for the presence of viability, we assumed a linear relationship
between the amount of viable myocardium and survival benefit of
revascularization. Twenty-nine studies (4,167 patients) met the inclusion
criteria. The optimal threshold for the presence of viability was
estimated to be 25.8% (95% CI: 16.6-35.0%) by positron emission tomography
using 18F-fluorodeoxyglucose-perfusion mismatch, 35.9% (95% CI:
31.6-40.3%) by stress echocardiography using contractile reserve or
ischemic responses, and 38.7% (95% CI: 27.7-49.7%) by single photon
emission computed tomography using thallium-201 or technetium-99m MIBI
myocardial perfusion. Conclusions: The calculated amount of viable
myocardium determined to lead to improved survival was different among
imaging techniques. Thus, separate cutoff values for imaging modalities
may be helpful in determining which patients with ICM benefit from
revascularization. Copyright 2010 by the American Society of Nuclear
Cardiology.
<2>
[Use Link to view the full text]
Accession Number
2010477362
Authors
Dimitrova K.R. Hoffman D.M. Geller C.M. Decastro H. Dienstag B. Tranbaugh
R.F.
Institution
(Dimitrova, Hoffman, Geller, Decastro, Dienstag, Tranbaugh) Division of
Cardiac Surgery, Beth Israel Medical Center, 317 East 17th Street, New
York, NY 10003, United States
Title
Endoscopic radial artery harvest produces equivalent and excellent midterm
patency compared with open harvest.
Source
Innovations: Technology and Techniques in Cardiothoracic and Vascular
Surgery. 5 (4) (pp 265-269), 2010. Date of Publication: July-August
2010.
Publisher
Lippincott Williams and Wilkins (250 Waterloo Road, London SE1 8RD, United
Kingdom)
Abstract
Objective: A recent multicenter study reported reduced patency of
aortocoronary bypass grafts when the saphenous vein was harvested by
endoscopic technique compared with patency of vein grafted after harvest
by the traditional "open" approach. Our aim was to compare the patency
rates of radial artery graft (RAG) harvested endoscopically with those
harvested using an open technique. Methods: Two cohorts were identified:
from January 1995 to January 2000, 724 consecutive patients had one or
both radial arteries harvested through an open technique, and from
February 2000 to January 2008, 727 consecutive patients had endoscopic
radial artery (RA) harvest. All patients who underwent symptom-indicated
angiography in our institution at any time after coronary artery bypass
grafting (CABG) surgery were identified. Results: Two hundred two patients
had angiograms for symptoms: 90 of these patients (119 RAG) had open RA
harvest and were studied 78.3 +/- 40 months (range, 1-156 months) after
CABG. The other 112 patients (148 RAG) had endoscopic RA harvest and
underwent angiography 36 +/- 24 months (range, 1-96 months) after CABG.
The two groups had identical demographics and risk profiles. Overall
patency of the "open" RAG was 78.9% versus 83.7% for the endoscopic group
(P = 0.3). Patency increased to 90% in both groups when the RAG was
anastomosed to a native coronary vessel with stenosis >80%. Conclusions:
Endoscopic and open RA harvesting techniques have equivalent and excellent
midterm and long-term patency rates in CABG patients studied by
angiography for recurrent symptoms of myocardial ischemia. The degree of
stenosis of the target vessel strongly influences the patency rate
independent of the harvesting technique. 2010 by the International
Society for Minimally Invasive Cardiothoracic Surgery.
<3>
[Use Link to view the full text]
Accession Number
2010477363
Authors
Schoenebeck J. Haddad M. Wegscheider K. Joubert-Huebner E. Reichenspurner
H. Detter C.
Institution
(Schoenebeck, Joubert-Huebner, Reichenspurner, Detter) Department of
Cardiovascular Surgery, University Heart Center Hamburg, Martinistrasse
52, 20246 Hamburg, Germany
(Haddad) Departments of Clinical Chemistry, University of Hamburg,
Hamburg, Germany
(Wegscheider) Medical Biometry and Epidemiology, University of Hamburg,
Hamburg, Germany
Title
Prospective, randomized study comparing two different minimized versus
conventional cardiopulmonary bypass systems.
Source
Innovations: Technology and Techniques in Cardiothoracic and Vascular
Surgery. 5 (4) (pp 270-277), 2010. Date of Publication: July-August
2010.
Publisher
Lippincott Williams and Wilkins (250 Waterloo Road, London SE1 8RD, United
Kingdom)
Abstract
Objective: Conventional cardiopulmonary bypass (CCPB) is a major trigger
of inflammatory response. We aimed to assess the impact of two different
minimized cardiopulmonary bypass systems (mini-CPB) with and without
Bioline-coating compared with CCPB regarding organ function, inflammatory
response, and early clinical outcome. Methods: In a prospective,
randomized study, 120 patients underwent elective coronary artery bypass
grafting and were randomized into three groups: mini-CPB using a
Bioline-coated (group A, n = 40) or an uncoated (group B, n = 40) circuit,
or CCPB (group C, n = 40). Cytokines (interleukin-6, interleukin-8, and
tumor necrosis factor-alpha), myocardial markers (creatine kinase [CK],
CK-MB, and troponin-T), hematocrit, and platelet counts were measured up
to 48 hours postoperatively. Early clinical outcome was assessed at 3
months postoperatively. Results: Demographics, number of distal
anastomoses, ventilation time, blood loss, intensive care unit, and
hospital stay were comparable (P = not significant). Extracorporeal
circulation and cross-clamp time were significantly longer in group A and
B versus C (P < 0.005). No significant differences could be found in the
release of interleukin-6, interleukin-8, and tumor necrosis factor-alpha
among groups. Myocardial markers were significantly reduced in group A and
B versus group C (P < 0.001). Hematocrit and platelet counts did not
differ among the groups. No differences could be found in early clinical
outcome up to 3 months. Conclusions: This study showed significant better
myocardial preservation with lower CK-MB and troponin-T levels in both
mini-CPB groups. No significant differences could be found in terms of
inflammation, hematologic effects, and early clinical outcome. 2010 by
the International Society for Minimally Invasive Cardiothoracic Surgery.
<4>
Accession Number
2010483030
Authors
Yamaguchi J. Hagiwara N. Ogawa H. Koyanagi R. Kasanuki H. Takagi A. Mori
F. Nagashima M. Yagi M.
Institution
(Yamaguchi, Hagiwara, Ogawa, Koyanagi, Kasanuki, Takagi, Mori, Nagashima,
Yagi) Department of Cardiology, Heart Institute of Japan, Tokyo Women's
Medical University, Tokyo, Japan
Title
Effect of amlodipine + candesartan on cardiovascular events in
hypertensive patients with coronary artery disease (from the Heart
Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary
Artery Disease [HIJ-CREATE] study).
Source
American Journal of Cardiology. 106 (6) (pp 819-824), 2010. Date of
Publication: 2010.
Publisher
Elsevier Inc. (360 Park Avenue South, New York NY 10010, United States)
Abstract
Combination therapy with calcium channel blockers and angiotensin II
receptor blockers is recommended as one of the effective therapies for
hypertension. However, it remains unclear whether this combination reduces
major adverse cardiovascular events (MACEs) in patients with hypertension
with coronary artery disease (CAD). The purpose of the present study was
to examine the effects of amlodipine plus candesartan on MACEs in patients
with hypertension with CAD. The study population was drawn from The Heart
Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary
Artery Disease (HIJ-CREATE), which was a multicenter, prospective,
randomized controlled trial including 2,049 patients with hypertension
with angiographically documented CAD. Subgroup analysis was performed in
patients treated with amlodipine at baseline (n = 388). The median
follow-up period was 4.3 years. Treatment using amlodipine plus
candesartan reduced the risk for MACEs by 39% (p = 0.015) compared to that
using amlodipine without angiotensin II receptor blockers. Among the
individual events constituting MACEs, the incidence of unstable angina
pectoris requiring hospitalization was significantly lower, by 52% (p =
0.007). In conclusion, amlodipine plus candesartan demonstrated a more
favorable effect on reducing cardiovascular events in patients with
hypertension with CAD compared to amlodipine-based therapy without
candesartan. 2010 Elsevier Inc. All rights reserved.
<5>
Accession Number
2010486464
Authors
Sleeper L.A. Reynolds H.R. White H.D. Webb J.G. Dzavik V. Hochman J.S.
Institution
(Sleeper) New England Research Institutes, 9 Galen Street, Watertown, MA
02472, United States
(Reynolds, Hochman) Cardiovascular Clinical Research Center, New York
University School of Medicine, New York, NY, United States
(White) Green Lane Cardiovascular Service, Auckland City Hospital,
Auckland, New Zealand
(Webb) St. Paul's Hospital, Vancouver, BC, Canada
(Dzavik) University of Toronto, Toronto, ON, Canada
Title
A severity scoring system for risk assessment of patients with cardiogenic
shock: A report from the SHOCK Trial and Registry.
Source
American Heart Journal. 160 (3) (pp 443-450), 2010. Date of Publication:
September 2010.
Publisher
Mosby Inc. (11830 Westline Industrial Drive, St. Louis MO 63146, United
States)
Abstract
Background: Early revascularization (ERV) is beneficial in the management
of cardiogenic shock (CS) complicating myocardial infarction. The severity
of CS varies widely, and identification of independent risk factors for
outcome is needed. The effect of ERV on mortality in different risk strata
is also unknown. We created a severity scoring system for CS and used it
to examine the potential benefit of ERV in different risk strata using
data from the SHOCK Trial and Registry. Methods: Data from 1,217 patients
(294 from the randomized trial and 923 from the registry) with CS due to
pump failure were included in a Stage 1 severity scoring system using
clinical variables. A Stage 2 scoring system was developed using data from
872 patients who had invasive hemodynamic measurements. The outcome was
in-hospital mortality at 30 days. Results: In-hospital mortality at 30
days was 57%. Multivariable modeling identified 8 risk factors (Stage 1):
age, shock on admission, clinical evidence of end-organ hypoperfusion,
anoxic brain damage, systolic blood pressure, prior coronary artery bypass
grafting, noninferior myocardial infarction, and creatinine >=1.9 mg/dL
(c-statistic = 0.74). Mortality ranged from 22% to 88% by score category.
The ERV benefit was greatest in moderate- to high-risk patients (P = .02).
The Stage 2 model based on patients with pulmonary artery catheterization
included age, end-organ hypoperfusion, anoxic brain damage, stroke work,
and left ventricular ejection fraction <28% (c-statistic = 0.76). In this
cohort, the effect of ERV did not vary by risk stratum. Conclusions:
Simple clinical predictors provide good discrimination of mortality risk
in CS complicating myocardial infarction. Early revascularization is
associated with improved survival across a broad range of risk strata.
2010 Mosby, Inc. All rights reserved.
<6>
Accession Number
2010486472
Authors
Van Kuijk J.-P. Voute M.T. Flu W.-J. Schouten O. Chonchol M. Hoeks S.E.
Boersma E.E. Verhagen H.J.M. Bax J.J. Poldermans D.
Institution
(Van Kuijk, Flu, Hoeks, Poldermans) Department of Anesthesiology, Erasmus
Medical Center, 's Gravendijkwal 230, 3015 CE Rotterdam, Netherlands
(Voute, Schouten, Verhagen) Department of Vascular Surgery, Erasmus
Medical Center, Rotterdam, Netherlands
(Chonchol, Bax) Division of Renal Diseases and Hypertension, University of
Colorado Denver Health Sciences Center, Aurora, CO, United States
(Boersma) Department of Clinical Epidemiology, Erasmus Medical Center,
Rotterdam, Netherlands
(Boersma) Department of Cardiology, Leiden University Medical Center,
Leiden, Netherlands
Title
The efficacy and safety of clopidogrel in vascular surgery patients with
immediate postoperative asymptomatic troponin T release for the prevention
of late cardiac events: Rationale and design of the Dutch
Echocardiographic Cardiac Risk Evaluation Applying Stress Echo-VII
(DECREASE-VII) trial.
Source
American Heart Journal. 160 (3) (pp 387-393), 2010. Date of Publication:
September 2010.
Publisher
Mosby Inc. (11830 Westline Industrial Drive, St. Louis MO 63146, United
States)
Abstract
Background: Major vascular surgery patients are at high risk for
developing asymptomatic perioperative myocardial ischemia reflected by a
postoperative troponin release without the presence of chest pain or
electrocardiographic abnormalities. Long-term prognosis is severely
compromised and characterized by an increased risk of long-term mortality
and cardiovascular events. Current guidelines on perioperative care
recommend single antiplatelet therapy with aspirin as prophylaxis for
cardiovascular events. However, as perioperative surgical stress results
in a prolonged hypercoagulable state, the postoperative addition of
clopidogrel to aspirin within 7 days after perioperative asymptomatic
cardiac ischemia could provide improved effective prevention for
cardiovascular events. Study design: DECREASE-VII is a phase III,
randomized, double-blind, placebo-controlled, multicenter clinical trial
designed to evaluate the efficacy and safety of early postoperative dual
antiplatelet therapy (aspirin and clopidogrel) for the prevention of
cardiovascular events after major vascular surgery. Eligible patients
undergoing a major vascular surgery (abdominal aorta or lower extremity
vascular surgery) who developed perioperative asymptomatic troponin
release are randomized 1:1 to clopidogrel or placebo (300-mg loading dose,
followed by 75 mg daily) in addition to standard medical treatment with
aspirin. The primary efficacy end point is the composite of cardiovascular
death, stroke, or severe ischemia of the coronary or peripheral arterial
circulation leading to an intervention. The evaluation of long-term safety
includes bleeding defined by TIMI criteria. Recruitment began early 2010.
The trial will continue until 750 patients are included and followed for
at least 12 months. Summary: DECREASE-VII is evaluating whether early
postoperative dual antiplatelet therapy for patients developing
asymptomatic cardiac ischemia after vascular surgery reduces
cardiovascular events with a favorable safety profile. 2010 Mosby, Inc.
All rights reserved.
<7>
Accession Number
20142215
Authors
Tchetche D. Dumonteil N. Sauguet A. Descoutures F. Luz A. Garcia O. Soula
P. Gabiache Y. Fournial G. Marcheix B. Carrie D. Fajadet J.
Institution
(Tchetche) Clinique Pasteur, Toulouse, France.
Title
Thirty-day outcome and vascular complications after transarterial aortic
valve implantation using both Edwards Sapien and Medtronic CoreValve
bioprostheses in a mixed population.
Source
EuroIntervention : journal of EuroPCR in collaboration with the Working
Group on Interventional Cardiology of the European Society of Cardiology.
5 (6) (pp 659-665), 2010. Date of Publication: Jan 2010.
Abstract
AIMS: Transcatheter aortic valve implantation (TAVI) is performed through
a transarterial approach with encouraging results in "one-type valve"
registries. We report 30-day data from a mixed population of patients
treated with either Medtronic CoreValve (MCV) or Edwards SAPIEN (ES)
valves. METHODS AND RESULTS: Forty-five patients had TAVI via the
transarterial approach (21 MCV and 24 ES). Mean age was 81.8+/-4.2 years,
Logistic EuroSCORE was 25.2+/-8.4%. Procedural success rate was 97.8%.
In-hospital death rate was 4.4%. Vascular complication rate was 8.9%. Of
MCV patients, 28.6% had a permanent pacemaker vs. 4.2% of ES patients;
p=0.02. No additional deaths were observed between discharge and 30 days.
NYHA functional class was improved at 30-days: 2.07+/-0.4 vs. 3.09+/-0.05,
p<0.0001. Mean transvalvular gradient was lower: 9.5+/-3.28 mmHg vs.
41.9+/-14 mmHg, p<0.0001. Overall 30-day MACE rate was 8.9%, similar
between MCV and ES patients. CONCLUSION: A routine policy of TAVI using
both MCV and ES valves is feasible without any worsening of procedural
success rates and 30-day outcomes. A wider population of high risk
patients with aortic stenosis can be offered a transarterial treatment.
This could be the next standard of care for teams performing TAVI.
<8>
Accession Number
20142220
Authors
Meredith I.T. Worthley S.G. Whitbourn R. Walters D. McClean D. Ormiston J.
Horrigan M. Wilkins G.T. Hendriks R. Matsis P. Muller D. Cutlip D.E.
Institution
(Meredith) MonashHEART Medical Centre, Melbourne, Australia.
Title
Long-term clinical outcomes with the next-generation Resolute Stent
System: a report of the two-year follow-up from the RESOLUTE clinical
trial.
Source
EuroIntervention : journal of EuroPCR in collaboration with the Working
Group on Interventional Cardiology of the European Society of Cardiology.
5 (6) (pp 692-697), 2010. Date of Publication: Jan 2010.
Abstract
AIMS: The 12-month results of RESOLUTE were favourable for the new
Resolute stent. Two-year safety and efficacy results from RESOLUTE have
been evaluated and are now reported. METHODS AND RESULTS: RESOLUTE was a
prospective, multicentre, non-randomised, single-arm, controlled trial of
the Resolute stent in 139 participants with symptomatic ischaemic heart
disease due to single de novo lesions in a native coronary artery. The
2-year rates of MACE (all-cause death, myocardial infarction, emergent
cardiac bypass surgery, and target lesion revascularisation [TLR]), death,
late stent thrombosis, target vessel revascularisation (TVR), and target
vessel failure (TVF) were assessed. Clinical events included two MACE (one
TLR; one non-cardiac death) occurring between year one and two resulting
in cumulative 2-year TLR, TVR, and TVF rates of 1.4%, 1.4%, and 7.9%,
respectively. One possible stent thrombosis event occurred in the first
year after stent implantation however no late or very late ARC-defined
definite and probable stent thromboses occurred through two years.
CONCLUSIONS: The 2-year data from RESOLUTE demonstrated no safety concerns
including no late stent thrombosis or loss of effectiveness with the
Resolute stent. The finding that few events occurred in year two is
encouraging, yet requires verification in a larger population.
<9>
Accession Number
2010483574
Authors
Voucharas C. Bisbos A. Moustakidis P. Tsilimingas N.
Institution
(Voucharas, Bisbos, Moustakidis) Division of Cardiothoracic Surgery,
Interbalkan Medical Center, Thessaloniki, Greece
(Tsilimingas) Department of Cardiovascular and Thoracic Surgery,
University of Thessaly, Larissa, Greece
Title
Open versus tunneling radial artery harvest for coronary artery grafting.
Source
Journal of Cardiac Surgery. 25 (5) (pp 504-507), 2010. Date of
Publication: September 2010.
Publisher
Blackwell Publishing Inc. (350 Main Street, Malden MA 02148, United
States)
Abstract
We present a less traumatic surgical technique for harvesting the radial
artery as a coronary artery bypass graft that does not require any special
equipment or skills. We prospectively randomized 40 patients undergoing
coronary artery bypass grafting with the radial artery into two groups on
the basis of harvest techniques: tunneling excision and conventional open
method. The less-invasive tunneling technique is safe, easily applicable,
and preferred by patients because of the superior cosmetic result. 2010
Wiley Periodicals, Inc.
<10>
Accession Number
2010483577
Authors
Alghamdi A.A. Singh S.K. Hamilton B.C.S. Yadava M. Holtby H. Van Arsdell
G.S. Al-Radi O.O.
Institution
(Alghamdi, Singh, Hamilton, Yadava, Van Arsdell, Al-Radi) Department of
Surgery, Divisions of Cardiovascular Surgery, United States
(Holtby) Department of Anesthesia, Hospital for Sick Children, University
of Toronto, Toronto, ON, Canada
Title
Early extubation after pediatric cardiac surgery: Systematic review,
meta-analysis, and evidence-based recommendations.
Source
Journal of Cardiac Surgery. 25 (5) (pp 586-595), 2010. Date of
Publication: September 2010.
Publisher
Blackwell Publishing Inc. (350 Main Street, Malden MA 02148, United
States)
Abstract
Objective: To derive evidence-based recommendations regarding early
extubation strategy after congenital cardiac surgery. Outcomes: Incidence
of total mortality, morbidity, reintubation, length, and costs of
intensive care unit and hospital stay. Evidence: Medline, Embase, and the
Cochrane-controlled trial register on the Cochrane library were searched
from the earliest achievable date of each database to present. No language
restrictions were applied. Retrieved reprints were evaluated according to
a priori inclusion criteria, and those included were critically appraised
using established internal validity criteria. Benefits and Harms: Early
extubation (in the operating room or <=6 hours after surgery) was
associated with a lower early mortality. There was a trend toward lower
ICU and hospital length of stays, lower hospital costs, and less
respiratory morbidity. There was no difference in the rate of reintubation
in those extubated early versus late. Conclusion: Early extubation appears
safe and is associated with reduction in length of ICU and hospital stay
without adverse effects on mortality or morbidity. However, studies to
date are poor, heterogeneous, and not suitable to determine a causal
effect. Therefore, there is need for a well-designed randomized clinical
trial to demonstrate the potential significant benefits of early
extubation. 2010 Wiley Periodicals, Inc.
<11>
Accession Number
2010476305
Authors
Ohashi T. Shibata R. Morimoto T. Kanashiro M. Ishii H. Ichimiya S. Hiro T.
Miyauchi K. Nakagawa Y. Yamagishi M. Ozaki Y. Kimura T. Daida H. Murohara
T. Matsuzaki M.
Institution
(Ohashi, Kanashiro, Ichimiya) Department of Cardiology, Yokkaichi
Municipal Hospital, Yokkaichi, Japan
(Ohashi, Shibata, Ishii, Murohara) Department of Cardiology, Nagoya
University Graduate School of Medicine, Nagoya, Japan
(Morimoto) Center for Medical Education, Kyoto University Graduate School
of Medicine, Kyoto, Japan
(Hiro) Division of Cardiology, Department of Medicine, Nihon University
School of Medicine, Tokyo, Japan
(Miyauchi, Daida) Department of Cardiology, Juntendo University School of
Medicine, Tokyo, Japan
(Nakagawa) Department of Cardiology, Tenri Hospital, Nara, Japan
(Yamagishi) Division of Cardiovascular Medicine, Kanazawa University
Graduate School of Medicine, Kanazawa, Japan
(Ozaki) Department of Cardiology, Fujita Health University, Toyoake, Japan
(Kimura) Department of Cardiovascular Medicine, Kyoto University Graduate
School of Medicine, Kyoto, Japan
(Matsuzaki) Division of Cardiology, Department of Medicine and Clinical
Science, Yamaguchi University Graduate School of Medicine, Ube, Japan
Title
Correlation between circulating adiponectin levels and coronary plaque
regression during aggressive lipid-lowering therapy in patients with acute
coronary syndrome: Subgroup analysis of JAPAN-ACS study.
Source
Atherosclerosis. 212 (1) (pp 237-242), 2010. Date of Publication:
September 2010.
Publisher
Elsevier Ireland Ltd (P.O. Box 85, Limerick, Ireland)
Abstract
Objective: The Japan assessment of pitavastatin and atorvastatin in acute
coronary syndrome (JAPAN-ACS) study demonstrated that aggressive
lipid-lowering therapy with a statin resulted in a significant regression
of coronary atherosclerotic plaques in patients with ACS. Adiponectin is
an adipocyte-derived protein with anti-atherogenic properties. Here, we
investigated the association between adiponectin levels and the change in
the plaque volume in ACS patients. Methods: Intravascular ultrasound
(IVUS)-guided percutaneous coronary intervention (PCI) was undertaken,
followed by the initiation of statin treatment, in 238 patients with ACS.
Follow-up IVUS was performed between 8 and 12 months after the PCI. The
percent change in the plaque volume (%PV) in a non-culprit coronary artery
segment was evaluated. The serum adiponectin and lipid parameters were
measured both at baseline and at the follow-up. Results: At baseline,
adiponectin was correlated positively with HDL-cholesterol and negatively
correlated with triglyceride, but no correlation was observed with the PV.
Adiponectin levels increased significantly from 7.8 +/- 4.6 mug/mL at
baseline to 10.3 +/- 6.9 mug/mL at the 8-12 months follow-up. The increase
in adiponectin was also associated with an increase of HDL-cholesterol and
decrease of triglyceride, however, no significant correlation was observed
with the %PV. A significantly higher incidence of major adverse cardiac
events (MACE) was observed in patients with hypo-adiponectinemia at
baseline. A multiple logistic regression analysis identified adiponectin
as a significant independent predictor of MACE. Conclusion: Adiponectin
levels measured after PCI could serve as a marker of MACE in patients with
ACS. 2010 Elsevier Ireland Ltd.
<12>
Accession Number
2010478254
Authors
Singh I.M. Holmes Jr. D.R.
Institution
(Singh) Fellow of Interventional Cardiology, Mayo Clinic, 200 First Street
SW SMH MB 4-523, Rochester, MN 55905, United States
(Holmes Jr.) Division of Cardiovascular Diseases, Mayo Clinic, 200 First
Street SW SMH MB 4-523, Rochester, MN 55905, United States
Title
Left atrial appendage closure.
Source
Current Cardiology Reports. 12 (5) (pp 413-421), 2010. Date of
Publication: September 2010.
Publisher
Current Medicine Group LLC (5 Marine View Plaza, Suite 218, Hoboken NJ
07030, United States)
Abstract
Stroke prevention is the primary goal in atrial fibrillation (AF) given
its clinical and socioeconomic impact. With AF, the prevalence of
thromboembolic stroke continues to rise and there is an urgent need to
develop better strategies of stroke prevention. Warfarin, although
effective when used appropriately, is burdened by underutilization, narrow
therapeutic windows, and life-threatening bleeding complications. Novel
pharmacologic agents have been plagued by off-target toxicity and only
modest improvement in bleeding complications over warfarin. Because most
thromboemboli arise from the left atrial appendage (LAA), surgical
exclusion of the LAA is often used in AF patients undergoing cardiac
surgery. Percutaneous device LAA closure has now been developed as an
adjunct and as an alternative to pharmacotherapy in patients with AF.
Promising randomized data are available with the WATCHMAN device, while
several other devices are in various stages of clinical and preclinical
development. 2010 Springer Science+Business Media, LLC.
<13>
Accession Number
2010478262
Authors
Goldberg S.L. Feldman T.
Institution
(Goldberg) University of Washington Medical Center, Seattle, WA, United
States
(Goldberg) Cardiac Dimensions, Inc., Kirkland, WA, United States
(Feldman) Evanston Hospital, Evanston, IL, United States
Title
Percutaneous mitral valve interventions: Overview of new approaches.
Source
Current Cardiology Reports. 12 (5) (pp 404-412), 2010. Date of
Publication: September 2010.
Publisher
Current Medicine Group LLC (5 Marine View Plaza, Suite 218, Hoboken NJ
07030, United States)
Abstract
The percutaneous management of valvular heart disease has recently been
receiving a great deal of interest as an area of great potential.
Innovative technologies are now being developed to treat mitral
regurgitation. Although there are established surgical techniques for
treating organic mitral regurgitation, the surgical management of
functional mitral regurgitation remains controversial, and such patients
have a poor prognosis. Therefore, a percutaneous treatment for functional
mitral regurgitation holds great clinical potential. Having a nonsurgical
approach available may be attractive to patients with organic mitral valve
regurgitation as well. Several approaches and devices have been designed
to treat specifically functional mitral regurgitation, and some of these
have been applied to humans in early-stage evaluations. The MitraClip
device (Abbott Laboratories, Abbott Park, IL) has been used to treat both
functional and degenerative mitral valve regurgitation and has been
compared to surgery in the EVEREST II (Endovascular Valve Edge-to-Edge
Repair Study II) randomized trial. Although the field of percutaneous
management of mitral regurgitation is at an early stage, it has been
demonstrated that percutaneous approaches can reduce mitral regurgitation,
suggesting there is a great deal of potential for clinical benefit to
patients with mitral regurgitation. 2010 Springer Science+Business Media,
LLC.
No comments:
Post a Comment